Immunotherapy combination improves outcomes in advanced kidney cancer

(Dana-Farber Cancer Institute) An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news